Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions

Lei Lei Wu

News Reporter

Arialys Therapeutics announced Tuesday that it tied the bow on a $58 million seed round to develop treatments specifically for brain disorders caused by immune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Aval­on's lat­est biotech clos­es $58M round as it pur­sues treat­ments for au­toim­mune brain con­di­tions

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions